PDGFRB and neoplasm: Sorafenib blocks receptor tyrosine kinase signaling, such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and RET, and inhibits downstream Raf serine/threonine kinase activity to prevent tumor growth by anti-angiogenic, anti-proliferative, and/or pro-apoptotic effects [56].